Ignite Creation Date:
2024-05-06 @ 7:43 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06102759
Status:
RECRUITING
Last Update Posted:
2023-10-26
First Post:
2023-10-22
Brief Title:
Adebrelimab and Fruquintinib Combined With PaclitaxelAlbumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
Phase II Clinical Study of Adebrelimab and Fruquintinib Combined With PaclitaxelAlbumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer After First-line Treatment With PD-1 Antibody Failed
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single-center open single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib and Adebrelimab combined with paclitaxelalbumin paclitaxel for second-line treatment of advanced gastric cancer
Detailed Description:
Since the first-line ICIs application of gastric cancer is mainly PD-1 antibody this study intends to screen first-line patients exposed to PD-1 antibody and with long survival PFS longer than 9 months to receive second-line PD-L1 antibody for re-challenge and combine with Fruquintinib and paclitaxel to explore whether it can further increase the effect of second-line treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None